IP Library Granted Patent US 7,129,248
Granted Patent B2
US 7,129,248 · App. 11/093,626 · Granted Oct 31, 2006

Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Assignee: Euro-Celtique, S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,129,248
App. No.
11/093,626
Granted
Oct 31, 2006
Kind
B2
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (18)

1. A process for preparing an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone comprising hydrogenating an oxycodone hydrochloride composition having at least 100 ppm 14-hydroxycodeinone in a suitable solvent to produce an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.

2. The process of claim 1 , wherein said hydrogenation is performed with a hydrogen donor and a catalyst.

3. The process of claim 1 wherein said hydrogenation is performed under reflux.

4. The process of claim 1 , wherein the solvent is an alcohol.

5. The process of claim 4 , wherein the alcohol is selected from the group consisting of methanol, ethanol and isopropanol.

6. The process of claim 1 , further comprising recovering the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone from the solvent.

7. The process of claim 6 , wherein the recovery step comprises crystallizing the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone and filtering the crystallized composition from the solvent.

8. The process of claim 6 , comprising further hydrogenating the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.

9. The process of claim 6 , wherein the oxycodone hydrochloride composition has a 14-hydroxycodeinone level of less than 15 ppm.

10. The process of claim 2 , wherein the hydrogenation is performed with a hydrogen donor.

11. The process of claim 10 , wherein the hydrogenation is further performed with a catalyst.

12. The process of claim 10 , wherein the hydrogen donor is selected from the group consisting of hydrogen gas, formic acid, indoline, cyclohexene, sodium borohydride, tetrahydroquinoline, 2,5-dihydrofuran, phosphoric acid, and combinations thereof.

13. The process of claim 1 , wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 15 ppm.

14. The process of claim 1 , wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 10 ppm.

15. The process of claim 1 , wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 5 ppm.

16. The process of claim 1 , wherein the hydrogenation produces an oxycodone composition having a 14-hydroxycodeinone level of between 15 ppm and 25 ppm, further comprising additional hydrogenation to produce an oxycodone hydrochloride composition comprising 14-hydroxycodeinone in an amount less than 10 ppm.

17. The process of claim 1 , wherein the hydrogenation produces an oxycodone composition having a 14-hydroxycodeinone level of between 10 ppm and 25 ppm, further comprising additional hydrogenation to produce an oxycodone hydrochloride composition comprising 14-hydroxycodeinone in an amount less than 5 ppm.

18. The process of claim 1 , wherein the hydrogenation step is performed without a hydrogen gas feed.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; P.F. LABORATORIES, INC. THE; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 024384/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2006
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 018597/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2005
From: CHAPMAN, ROBERT; RIDER, LONN S.; HONG, QI; KUPPER, ROBERT; KYLE, DONALD
To: EURO-CELTIQUE S.A.
Reel/Frame 016574/0660 →
Continuity (6)
Provisional Application 6065177800 · Feb 10, 2005
Provisional Application 6064862500 · Jan 31, 2005
Provisional Application 6062007200 · Oct 18, 2004
Provisional Application 6060153400 · Aug 13, 2004
Provisional Application 6057749200 · Mar 30, 2004
Related Publication 20050222188A1 · Oct 6, 2005